Kirkwood F Adams Jr
Overview
Explore the profile of Kirkwood F Adams Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
75
Citations
3952
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sherwood A, Blumenthal J, Mentz R, Koch G, Rogers J, Chang P, et al.
ESC Heart Fail
. 2024 May;
11(5):2627-2636.
PMID: 38715254
Aims: The objective of this study was to examine associations between elevated depressive symptoms and increased risk of adverse clinical events patients with heart failure and reduced ejection fraction (HFrEF),...
2.
Cotter G, Davison B, Adams Jr K, Ambrosy A, Atabaeva L, Beavers C, et al.
Eur J Heart Fail
. 2023 Dec;
26(1):1-4.
PMID: 38124462
No abstract available.
3.
Sherwood A, Blumenthal J, Mentz R, Koch G, Rogers J, Chang P, et al.
medRxiv
. 2023 Oct;
PMID: 37808654
Background: Prior studies have demonstrated an association of depression with adverse clinical outcomes in patients with HFrEF, but the possible mechanisms responsible for the association are not unserstood. Methods: 142...
4.
Davison B, Takagi K, Edwards C, Adams Jr K, Butler J, Collins S, et al.
Am J Cardiol
. 2022 Aug;
180:72-80.
PMID: 35933224
Previous studies have suggested that the neutrophil-to-lymphocyte ratio (NLR) is a novel yet readily evaluable inflammatory biomarker that may be useful for determining cardiovascular prognosis during acute episodes. The study...
5.
Giblin E, Adams Jr K, Hill L, Fonarow G, Williams F, Sharma P, et al.
Am J Cardiol
. 2019 Nov;
124(12):1900-1906.
PMID: 31679641
Underuse of hydralazine/nitrate (HYD/NIT) in black patients with heart failure and reduced ejection fraction (HFrEF) has been previously described, but whether this important treatment gap persists in contemporary practice is...
6.
Psotka M, Gottlieb S, Francis G, Allen L, Teerlink J, Adams Jr K, et al.
J Am Coll Cardiol
. 2019 May;
73(18):2345-2353.
PMID: 31072579
The term "inotrope" is familiar and intimately connected with pharmaceuticals clinically used for treatment of low cardiac output with cardiogenic shock. Traditional inotropic agents exert their effect by modulating calcium...
7.
Parikh K, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan D, et al.
Circ Genom Precis Med
. 2018 Oct;
11(8):e002210.
PMID: 30354340
Background In heart failure (HF) with reduced ejection fraction, 2 clinical trials, the BEST (β-Blocker Evaluation of Survival Trial) and HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise...
8.
Vodovar N, Mebazaa A, Januzzi Jr J, Murtagh G, Stough W, Adams Jr K, et al.
Int J Cardiol
. 2018 Feb;
254:215-221.
PMID: 29407093
Natriuretic peptides (NPs) are recommended by international guidelines to exclude non-heart failure causes of acute dyspnea and to assess prognosis. NPs are commonly used as an entry criterion for clinical...
9.
Sherwood A, Hill L, Blumenthal J, Adams Jr K, Paine N, Koch G, et al.
Am Heart J
. 2017 Sep;
191:82-90.
PMID: 28888274
Introduction: Cardiovascular (CV) reactivity to psychological stress has been implicated in the development and exacerbation of cardiovascular disease (CVD). Although high CV reactivity traditionally is thought to convey greater risk...
10.
Adams Jr K, Giblin E, Pearce N, Patterson J
Pharmacotherapy
. 2017 Apr;
37(6):645-656.
PMID: 28394465
Heart failure is well recognized as a major public health concern not only due to severe and frequent adverse health outcomes but also related to the major financial burden this...